Lightnews — Scholar-powered news

Neurooncology Tuebingen @neurooncotue.bsky.social · 12h

Now Surender Surender on stage, presenting our data on CDK4/6 inhibition in experimental glioma!
@eanoassociation.bsky.social
@ghtabatabai.bsky.social
@hih-tuebingen.bsky.social

4 9

Neurooncology Tuebingen @neurooncotue.bsky.social · 15h

Great talk by @ghtabatabai.bsky.social about time management in academia
@eanoassociation.bsky.social

2 5

Neurooncology Tuebingen @neurooncotue.bsky.social · 1d

Great poster session with nice discussions about our current work!
@eanoassociation.bsky.social
@ghtabatabai.bsky.social
@hannes-becker1996.bsky.social
@nihalolcaydogan.bsky.social
@hih-tuebingen.bsky.social

1 5

Neurooncology Tuebingen @neurooncotue.bsky.social · 1d

Nice opportunity to present our data on regorafenib in combination with navitoclax at @eanoassociation.bsky.social
@hannes-becker1996.bsky.social
@ghtabatabai.bsky.social

Ghazaleh Tabatabai @ghtabatabai.bsky.social · 1d

And now it‘s Hannes Becker on stage, presenting our data at EANO2025 👍🏼🙌 @neurooncotue.bsky.social

2 3

Neurooncology Tuebingen @neurooncotue.bsky.social · 1d

@eanoassociation.bsky.social

Ghazaleh Tabatabai @ghtabatabai.bsky.social · 1d

Just happening. Max Niyazi on stage at EANO 2025 👍🏼💡

1 2

Reposted by Neurooncology Tuebingen

Ghazaleh Tabatabai @ghtabatabai.bsky.social · 1d

Just happening. Max Niyazi on stage at EANO 2025 👍🏼💡

2 5

Neurooncology Tuebingen @neurooncotue.bsky.social · 1d

Great comprehensive talk by @ghtabatabai.bsky.social to give insights into CRISPR screen.
More to come!
@eanoassociation.bsky.social

2 5

Reposted by Neurooncology Tuebingen

EANO @eanoassociation.bsky.social · Aug 23

🧠 Just published in Neuro-Oncology: A comprehensive consensus review by @neuroonc.bsky.social and EANO on current management and future directions in adult #Glioblastoma care. Explore key recommendations and research priorities.
🔗 academic.oup.com/neuro-oncolo...

#NeuroOncology

1 5 11

Reposted by Neurooncology Tuebingen

EANO @eanoassociation.bsky.social · 22d

🚨 At #EANO2025, we already expect more than 1,200 participants! Don’t miss out on this fantastic experience to meet experts in the field of #NeuroOncology from all over the world. Registration is still open eano.eu/eano2025/ We can’t wait to see you in #Prague!

3 8

Reposted by Neurooncology Tuebingen

EANO @eanoassociation.bsky.social · 24d

🧠 Recently published in Neuro-Oncology: EANS–EANO Guidelines on the Extent of Resection in Gliomas. We’re proud to share the outcome of collaborative effort by the joint task force of EANS and EANO, providing evidence-based recommendations for clinical practice.
🔗 academic.oup.com/neuro-oncolo...

10 29

Neurooncology Tuebingen @neurooncotue.bsky.social · 19d

Innovative trial design, thank you for the opportunity for being part of it!

EANO @eanoassociation.bsky.social · Sep 9

🧠 The phase 1/2 N2M2 umbrella trial lead by former EANO president @wickwolfgang.bsky.social has just been published in Nature Medicine
🔗 www.nature.com/articles/s41...

#NeuroOncology #EANOessentials #BrainTumors #CancerResearch

Molecularly matched targeted therapies plus radiotherapy in glioblastoma: the phase 1/2a N2M2 umbrella trial - Nature Medicine

In a phase 1/2a umbrella trial in patients with glioblastoma matching targeted therapies according to tumor molecular profiling, temsirolimus plus radiotherapy improved PFS compared to standard of car...

www.nature.com

1 1

Neurooncology Tuebingen @neurooncotue.bsky.social · 19d

Extremely happy that we could have contributed!

Michael Platten, MD @michael-platten.bsky.social · Jul 29

Excited to announce that we have completed accrual of the INTERCEPT-H3 trial (NCT04808245). This phase 1 first-in-human trial explores safety and immunogenicity of a long peptide vaccine targeting the clonal driver mutation H3K27M in adult patients with newly diagnosed diffuse midline gliomas 1/

1 1

Neurooncology Tuebingen @neurooncotue.bsky.social · Jun 3

Thank you for having the opportunity to present our data at this year DGNC in Hanover.
#DGNC2025

1 4

Reposted by Neurooncology Tuebingen

Ghazaleh Tabatabai @ghtabatabai.bsky.social · Apr 20

Almost 25 year old T-shirt, reminds me of great experience at MGH/HMS 2000/2001, @harvard.edu - hard to see this institution under pressure now, and impressed by the integrity and resilience of Harvard leadership (more on LinkedIn) 🙌 #Harvard #AcademicFreedom #ScienceForDemocracy #ScienceMatters

3 12

Neurooncology Tuebingen @neurooncotue.bsky.social · Feb 20

Happy to represent Tuebingen in this initiative!
#aufstehenfuerdemokratie

Ghazaleh Tabatabai @ghtabatabai.bsky.social · Feb 20

Tübingen 20 Feb 2025
#aufstehenfuerdemokratie

1 3

Reposted by Neurooncology Tuebingen

Ghazaleh Tabatabai @ghtabatabai.bsky.social · Feb 12

Tübingen 12 Feb 2025
Geschwister Scholl Platz
Democracy needs facts
Science needs Democracy.
#aufstehenfuerdemokratie

5 12

Neurooncology Tuebingen @neurooncotue.bsky.social · Feb 3

Congrats!

Neurooncology Tuebingen @neurooncotue.bsky.social · Jan 16

We are more than happy that our publication "The Immunopeptidomic Landscape of Ependymomas Provides Actionable Antigens for T Cell-Based Immunotherapy" is accepted by Neurooncology Advances.

academic.oup.com/noa/advance-...

Check it out ;)

@unituebingen.bsky.social
@hih-tuebingen.bsky.social

The Immunopeptidomic Landscape of Ependymomas Provides Actionable Antigens for T Cell-Based Immunotherapy

AbstractBackground. Ependymoma are primary tumors of the nervous system. Due to their growth pattern, many ependymomas can be managed with neurosurgical re

academic.oup.com

3 7

Reposted by Neurooncology Tuebingen

Universität Tübingen @unituebingen.bsky.social · Jan 13

👍 Herzlich Willkommen auf dem Bluesky-Account der #unituebingen. Wir posten ab sofort hier und auf unseren anderen Kanälen, z.B. Instagram, Facebook, LinkedIn, Mastodon. Unsere Aktivitäten auf X haben wir beendet.

8 14 88

Neurooncology Tuebingen @neurooncotue.bsky.social · Jan 7

Happy to see this finally out after a long team effort! 🎉🎉🎉
@hih-tuebingen.bsky.social
@ghtabatabai.bsky.social

Ghazaleh Tabatabai @ghtabatabai.bsky.social · Jan 7

NEW publication from our Lab 🥳💫🥳Genome-wide CRISPR-Cas9 screens identify identify BCL family members as modulators of response to regorafenib in experimental glioma. @neurooncotue.bsky.social

pubmed.ncbi.nlm.nih.gov/39756423/

Genome-wide CRISPR-Cas 9 screens identify BCL family members as modulators of response to regorafenib in experimental glioma - PubMed

This preclinical study uses a functional genomics-based target discovery approach with subsequent validations involving regorafenib. It serves as a biological rationale for clinical translation. Parti...

pubmed.ncbi.nlm.nih.gov

1 6

Reposted by Neurooncology Tuebingen

Ghazaleh Tabatabai @ghtabatabai.bsky.social · Dec 25

Merry Christmas and very best wishes für 2025!
@hih-tuebingen.bsky.social @unituebingen.bsky.social @neurooncotue.bsky.social

1 1 7

Reposted by Neurooncology Tuebingen

International Consortium on Meningiomas (ICOM) @icomeningioma.bsky.social · Dec 18

New insights into #meningiomas, with The Brain Tumour Charity’s funding and led by @gelarehzadeh.bsky.social, has been included in their #Research Highlights of 2024.

Read more about it here: www.thebraintumourcharity.org/news/researc...

1 4

Reposted by Neurooncology Tuebingen

Mathias Jucker @mathiasjucker.bsky.social · Dec 16

Two flagship chair professorships for neurodgenerative diseases in Tübingen, Germany. Both affiliated with our university @hih-tuebingen.bsky.social and the German Center for Neurodegenerative diseases @dzne.science. Apply and join us!
www.nature.com/naturecareer...
www.nature.com/naturecareer...

Nature Careers | Science jobs | Choose from 1,225 live vacancies

Search for your next job from 1,225 live vacancies, or upload your CV now and let recruiters find you

nature.com

10 10

Reposted by Neurooncology Tuebingen

Hertie-Institut für klinische Hirnforschung (HIH) @hih-tuebingen.bsky.social · Dec 17

📢The Faculty of Medicine at the University of Tübingen invites applications for a position at the Hertie Center for Neurology for an Endowed #Professorship (W3) in #Neurology with a Focus on #Neurodegenerative #Diseases, available by 1 October 2026, potentially earlier
Full PDF: tinyurl.com/y6bfky83

3 5

Reposted by Neurooncology Tuebingen

International Consortium on Meningiomas (ICOM) @icomeningioma.bsky.social · Dec 16

@ghtabatabai is a neurologist and a physician scientist at the University of Tübingen and the Managing Director Neurology at the University Hospital Tübingen.

Her research includes target discovery & validation, molecular mechanisms of treatment resistance, & novel delivery routes to brain tumors.

Member Spotlight: Dr. Ghazaleh Tabatabai

4 7